Ph+ ALL research hub

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

This study is looking at a new treatment called olverembatinib for people recently diagnosed with a type of blood cancer called Philadelphia chromosome-positive Acute Lymphoblastic Leukaemia (Ph+ ALL). It compares this new drug with standard treatments to see if it works better and is safe.